A series of cardiometabolic-related news items has been observed from Roche/Hanmi, Lilly, Lexicon, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Kailera Therapeutics released its Q2 ’26 earnings report (view press release) and appointed a new CTO (view press release); Zealand Pharma hosted its Q2 ’26 earnings call (press release; slides); and Biomea Fusion dosed the first patient in its OPAL study evaluating icovamenib in combination with semaglutide for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Insulet, NewAmsterdam Pharma, Protagonist Therapeutics, Biomea Fusion, Vivani Medical, and CVS Health. Below, FENIX provides highlights and insights for the respective news items.
On the second day of the ADA 2026 conference, nine cardiometabolic-related news items have been observed from Pfizer, Abbott, Novo Nordisk, Hengrui/Kailera Therapeutics, Insulet, Dexcom, MannKind, Biomea Fusion, and Tidepool. Below, FENIX provides context and analysis for the announcements.
A series of cardiometabolic-related news items has been observed from Boehringer Ingelheim, Rocket Pharmaceuticals, Novartis, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items, including thoughts on how BI’s Ph3 survodutide data may have meaningful implications on obesity market pricing dynamics.
A series of cardiometabolic-related news items has been observed by Novo Nordisk, Boehringer Ingelheim, Pfizer, Merck, Fractyl Health, Biomea Fusion, and BrightGene Bio-Medical Technology. Below, FENIX provides highlights and insights for the respective news items.
On the fourth and final day of JPM 2026, FENIX has provided coverage of presentations by Inventiva Pharma, Jiangsu Hengrui Pharmaceuticals, Lexicon Pharmaceuticals, Biomea Fusion, and Esperion. Separately, one CVRM-related news item has been observed: FDA has delayed CNPV approval of Tzield and orforglipron (view article). Below, FENIX provides highlights and insights from the JPM presentations as well as insight into the CNPV delays.
Three cardiometabolic-related news items have been observed: A Delaware court denied Pfizer’s request to temporarily block Novo’s amended bid for Metsera (press release); MannKind hosted its Q3 ‘25 earnings call (press release; slides); and Biomea Fusion released its Q3 ‘25 earnings report (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly launched a new OSA campaign with Shaquille O’Neal titled, “Don’t Sleep on OSA” (view press release); Biomea Fusion dosed the first patient in its Ph1 study of BMF-650 (QD oral GLP-1RA) in otherwise healthy overweight/obese patients (view press release); and Fibronostics completed the acquisition of Stone Clinical Laboratories for non-invasive diagnostic testing for MASH/MASLD (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Biomea Fusion, AstraZeneca, Ionis Pharmaceuticals, Hanmi Pharmaceuticals, Fractyl Health, and MannKind. Below, FENIX provides highlights and insights for the respective news items.